Cardinal Health (CAH) is highlighted as a strong momentum pick, boasting a Zacks Rank #2 (Buy) and a Momentum Style Score of A. The prescription drug distributor has demonstrated significant outperformance, with shares climbing 68.94% over the past year, far exceeding the S&P 500's 13.97% gain and its industry's performance. This robust price action is further supported by positive earnings estimate revisions, as six full-year estimates have moved higher in the last two months, increasing the consensus from $9.45 to $9.79.
Cardinal Health (CAH), a prescription drug distributor, currently holds a Zacks Rank #2 (Buy) and a Momentum Style Score of A, indicating strong near-term potential based on Zacks' methodology which suggests such ratings historically outperform the market over a one-month period. This assessment is supported by a strongly positive sentiment score of 0.85 and a bullish tone. The company has demonstrated significant price outperformance across multiple timeframes. Shares are up 68.94% over the past year, substantially exceeding the S&P 500's 13.97% gain, and have risen 36.13% quarterly versus the S&P 500's 6.44%. Weekly and monthly gains of 6.76% and 29.83% respectively also significantly outpace its industry's performance, supported by an average 20-day trading volume of 2,610,722 shares. Further bolstering the positive outlook are robust earnings estimate revisions. Over the past two months, six full-year earnings estimates have moved higher with no downward revisions, boosting the consensus from $9.45 to $9.79. Similarly, five estimates for the next fiscal year have been revised upwards, with no negative adjustments, signaling sustained analyst confidence.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.85
Ticker Sentiment
